HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

AIMS: Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is a large randomized trial assessing the effects of extended release (ER) niacin in patients at high risk of vascular events. METHODS AND RESULTS: Prior to randomization, 4...

Full description

Saved in:
Bibliographic Details
Main Authors: Haynes, Richard, Jiang, Lixin, Hopewell, Jemma C, Li, Jing, Chen, Fang, Parish, Sarah, Landray, Martin J., Collins, Rory, Armitage, Jane, Collins, R., Armitage, J., Baigent, C., Chen, Z., Landray, M., Chen, Y., Jiang, L., Pedersen, T., Bowman, L., Chen, F., Hill, M., Haynes, R., Knott, C., Rahimi, K., Tobert, J., Sleight, P., Simpson, D., Parish, S., Baxter, A., Lay, M., Bray, C., Wincott, E., Leijenhorst, G., Skattebol, A., Moen, G., Mitchel, Y., Kuznetsova, O., MacMahon, S., Kjekshus, J., Hill, C., Lam, T.H., Sandercock, P., Peto, R., Hopewell, J.C.
Format: Artigo
Language:Inglês
Published: Oxford University Press 2013
Subjects:
Fasttrack Clinical
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3640201/
https://ncbi.nlm.nih.gov/pubmed/23444397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/eht055
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items